Randy Dotinga
Randy Dotinga is a medical writer based in San Diego, Calif.
Test predicts PCSM at 10 years post prostatectomy
New research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.
HIFU results in low morbidity, QoL preservation
Another study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.
Hydroxycitrate may have utility in treating stones
A new laboratory study suggests that a widely available nutritional supplement has potential to become a new treatment for the wide majority of kidney stones. Clinical research is still pending, however, and there are important caveats about the findings.
4 Tips for making more money
The difference between making a little or a lot could be as simple as your communications approach.
Meta-analysis links LUTS to heart disease in men
A new meta-analysis links moderate-to-severe lower urinary tract symptoms (LUTS) to heart disease in men, possibly because unhealthy lifestyles boost the risks of both conditions.
Study data may help risk stratify microhematuria Dx
A recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.
Big talk about breast reconstruction
Two plastic surgeons are sick of seeing huge scars, no nipples and “ugly” breast reconstruction results.
Penile transplant: Procedure raises technical, ethical issues
Here are the answers to frequently asked questions about the technical, financial, and ethical issues surrounding penile transplantation surgery.
How technology revolutionized the business of tattoo removal
How technology revolutionized the business of tattoo removal
Tattoo removal isn’t a simple, painless, or inexpensive process. Dig deep and learn how technology has changed the process.
Sonidegib offers new option for basal cell cancer
A newly approved medication called sonidegib (Odomzo) gives physicians a second option in a class of medications designed to treat a small number of patients who suffer from locally advanced basal cell carcinoma and meet other criteria. Learn more
  • 1
  • 2